CDR-Life develops antibody therapeutics targeting intracellular proteins presented on the major histocompatibility complex (MHC). The company uses its M-gager® technology to generate MHC-specific antibody-based T cell engagers for tumor-specific intracellular antigens.

CDR-Life

CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to a wide range of cancer antigens. We are leveraging this platform to advance a pipeline of potent and selective TCE therapeutics targeting intracellular and surface tumor antigens. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to empower patients’ own immune systems to eliminate tumors.

CDR-Life Inc.

Honored to be recognized by Labiotech.eu as a Swiss biotech to watch! Curious about our innovative T-cell engagers? Discover how we're harnessing the immune system to fight cancer at www.cdr-life.com.

A pleasure to present results in our joint poster with Boehringer Ingelheim at ARVO. Together we are working to bring a much-needed treatment option to the millions of patients who are living with geographic atrophy disease. #ARVO2024

Great news! CDR-Life Inc. expands its innovative cancer therapy portfolio with the addition of two highly tumor-targeted T cell engagers (TCE):
 
- CDR813: A powerhouse T cell engager targeting PRAME in HLA-A*02:01 patients. PRAME is a clinically validated pan-cancer target expressed in a broad set of tumors including non-small cell lung cancer, endometrial cancer, melanoma and ovarian cancer but not in normal tissue. This bi-valent, bi-specific antibody shows unparalleled potency and precision.
- CDR505: Breaking new ground with a T cell engager for KK-LC-1 in HLA-A01 patients. This expands treatment possibilities beyond the common HLA-A02 focus to benefit a large patient population with high unmet need.

These additions strengthen CDR-Life's mission to develop targeted cancer therapies for broader patient populations. Read more: https://bit.ly/4bldGNA

CDR-Life CEO Christian Leisner spoke with Drug Discovery World about methods for increasing access to antigens and improving immunotherapy treatments. Read the full article here: https://lnkd.in/e-gYrXKm

We are thrilled to announce the initiation of enrollment for the Phase 1 trial of CDR404, our lead program in development as a precision immunotherapy for solid tumors. The study was published as an online presentation at #ASCO24
Based on the company’s unique M-gager® technology, CDR404 is a first-of-its-kind, antibody-based bivalent and bispecific MAGE-A4 T-cell engager (TCE) for the treatment of MAGE-A4 positive solid tumors. The Phase I study evaluating CDR404 is actively enrolling at sites in the U.S. and Europe. 

Read more: https://bit.ly/3UT8GcQ

Great article in SCRIP where CDR-Life CEO Christian Leisner details his predictions on the role that T-cell engagers will play in the development of solid tumor therapies: https://bit.ly/4bAjTXs

COM:CDR-LIFE

CDR-Life

Analysis Not Available